Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 72Breast Neoplasms 9Neoplasm Metastasis 8Prostatic Neoplasms, Castration-Resistant 6Neoplasms 5Metastatic Castration-resistant Prostate Cancer 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Prostate Cancer Metastatic 3Metastatic Castration Resistant Prostate Cancer 3Bulbo-Spinal Atrophy, X-Linked 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Metastatic Hormone Sensitive Prostate Cancer 2Melanoma 2mCRPC 1Urinary Bladder Diseases 1Urethral Neoplasms 1Ureteral Neoplasms 1Ureteral Diseases 1Solid Tumours 1Small Cell Lung Carcinoma 1Seizures 1Salivary Cancer 1Recurrent Endometrial Endometrioid Adenocarcinoma 1Pancreatic Neoplasms 1Non-metastatic, Hormone naïve Prostate Cancer 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms, Squamous Cell 1Metastatic Progressive Castration-resistant Prostate Cancer 1

Interventions

enzalutamide 2Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Metastatic Hormone Sensitive Prostate Cancer × enzalutamide × Clear all
NCT04076059 2026-04-17

China ARCHES

Astellas Pharma Inc

Phase 3 Active not recruiting
180 enrolled 24 charts
Genitourinary

Metastatic Hormone Sensitive Prostate Cancer

NCT02677896 2025-10-24

ARCHES

Astellas Pharma Inc

Phase 3 Completed
1,150 enrolled 23 charts 1 FDA
Genitourinary

Metastatic Hormone Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡